千金药业
(600479)
| 流通市值：43.44亿 | | | 总市值：51.09亿 |
| 流通股本：4.19亿 | | | 总股本：4.92亿 |
| 报告期 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 970,265,534.34 | 3,628,843,106.61 | 2,718,335,546.6 | 1,817,998,691.42 |
| 营业收入 | 970,265,534.34 | 3,628,843,106.61 | 2,718,335,546.6 | 1,817,998,691.42 |
| 二、营业总成本 | 883,983,897.86 | 3,248,878,976.3 | 2,458,728,936.98 | 1,636,266,894.81 |
| 营业成本 | 495,553,589.22 | 1,858,832,653.58 | 1,362,590,676.64 | 909,585,978.69 |
| 税金及附加 | 9,490,826.77 | 40,945,051.55 | 30,606,071.88 | 20,548,964.16 |
| 销售费用 | 269,910,365.27 | 875,029,294.97 | 721,941,833.62 | 473,367,807.23 |
| 管理费用 | 68,488,783.26 | 306,055,030.15 | 212,501,698.23 | 133,372,368.57 |
| 研发费用 | 38,971,545.75 | 185,600,017.47 | 144,903,869.25 | 104,183,648.41 |
| 财务费用 | 1,568,787.59 | -17,583,071.42 | -13,815,212.64 | -4,791,872.25 |
| 其中:利息费用 | - | 52,966.67 | 48,833.34 | 36,566.67 |
| 其中:利息收入 | 301,932.9 | 23,304,730.3 | 18,259,633.5 | 8,344,887.26 |
| 三、其他经营收益 | | | | |
| 加:公允价值变动收益 | 283,598.66 | 2,407,585.49 | 1,539,015.05 | 1,372,771.77 |
| 加:投资收益 | 10,876,693.16 | 44,191,162.06 | 42,442,567.56 | 18,803,638.62 |
| 资产处置收益 | 168,864.47 | 1,875,639.98 | 1,457,271.84 | 8,827.08 |
| 资产减值损失(新) | 260,017.03 | -4,067,560.71 | -668,324.6 | -2,038,165.9 |
| 信用减值损失(新) | -9,753,154.9 | -2,492,378.46 | -12,209,952.8 | -10,132,100.74 |
| 其他收益 | 9,282,850.65 | 15,373,169.71 | 8,420,964.98 | 5,547,761.33 |
| 四、营业利润 | 97,400,505.55 | 437,251,748.38 | 300,588,151.65 | 195,294,528.77 |
| 加:营业外收入 | 368,057.7 | 1,244,274.61 | 493,359.52 | 231,336.25 |
| 减:营业外支出 | 1,211,874.62 | 3,394,343.21 | 2,369,147.5 | 1,153,527.51 |
| 五、利润总额 | 96,556,688.63 | 435,101,679.78 | 298,712,363.67 | 194,372,337.51 |
| 减:所得税费用 | 12,364,748.05 | 59,430,879.02 | 40,479,493.43 | 20,336,376.12 |
| 六、净利润 | 84,191,940.58 | 375,670,800.76 | 258,232,870.24 | 174,035,961.39 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | 84,191,940.58 | 375,670,800.76 | 258,232,870.24 | 174,035,961.39 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | 75,003,617.18 | 286,293,094.19 | 187,355,173.74 | 127,725,142.44 |
| 少数股东损益 | 9,188,323.4 | 89,377,706.57 | 70,877,696.5 | 46,310,818.95 |
| 扣除非经常损益后的净利润 | 72,330,449.94 | 279,393,713.73 | 169,638,123.2 | 117,897,726.27 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | 0.15 | 0.66 | 0.45 | 0.3 |
| (二)稀释每股收益 | 0.15 | 0.66 | 0.45 | 0.3 |
| 八、其他综合收益 | -458.94 | 183,896.35 | 524,130.45 | 524,144.56 |
| 归属于母公司股东的其他综合收益 | -458.94 | 183,896.35 | 524,130.45 | 524,144.56 |
| 九、综合收益总额 | 84,191,481.64 | 375,854,697.11 | 258,757,000.69 | 174,560,105.95 |
| 归属于母公司股东的综合收益总额 | 75,003,158.24 | 286,476,990.54 | 187,879,304.19 | 128,249,287 |
| 归属于少数股东的综合收益总额 | 9,188,323.4 | 89,377,706.57 | 70,877,696.5 | 46,310,818.95 |
| 公告日期 | 2026-04-29 | 2026-04-29 | 2025-10-30 | 2025-08-30 |
| 审计意见(境内) | | 标准无保留意见 | | |